Business
Appointment of Nominated Adviser and Sole Broker
Appointment of Nominated Adviser and Sole Broker.
About this update from Allergy Therapeutics Plc
[{"type":"text","content":"\n\n\nAllergy Therapeutics plc\n(\"Allergy Therapeutics\" or the \"Company\" or the \"Group\")\n \nAppointment of Nominated Adviser and Corporate Broker\n \n22 July 2024: Allergy Therapeutics (AIM: AGY), the fully integrated commercial biotechnology company specialising in allergy vaccines, is pleased to announce the appointment of Cavendish Capital Markets Limited as Nominated Adviser and Corporate Broker with immediate effect.\n \n- ENDS -\n \nFor further information, please contact:\n \nAllergy Therapeutics\nManuel Llobet, Chief Executive Officer\nShaun Furlong, Chief Financial Officer\n+44 (0)1903 845 820\n \nCavendish Capital Markets Limited (Nominated Adviser and Broker)\nGeoff Nash /Giles Balleny/Seamus Fricker / Rory Sale\nNigel Birks/Tamar Cranford Smith - Sales\n+44 (0)20 7220 0500\n \nICR Consilium\nMary-Jane Elliott / David Daley / Davide Salvi\n+44 (0)20 3709 5700\[email protected]\n \nAbout Allergy Therapeutics\n \nAllergy Therapeutics is an international commercial biotechnology company, headquartered in the UK, focussed on the treatment and diagnosis of allergic disorders, including aluminium free immunotherapy vaccines that have the potential to cure disease. The Group sells proprietary and third-party products from its subsidiaries in nine major European countries and via distribution agreements in an additional ten countries. Its broad pipeline of products in clinical development includes vaccines for grass, tree, house dust mite and peanut. For more information, please see www.allergytherapeutics.com.\n\n","length":3957,"tagName":"div"}]